Drug intelligence / Profile preview

nimustine + pegfilgrastim + teniposide

Development stage: Unknown
Lead developer: Daiichi Sankyo
Modality: Recombinant Proteins and Enzymes, Small Molecules
Administration: Intravenous, Subcutaneous

Overview

A combination therapy consisting of nimustine (an alkylating agent), pegfilgrastim (a long-acting granulocyte colony-stimulating factor), and teniposide (a topoisomerase II inhibitor). This combination would likely be used in cancer treatment protocols where nimustine and teniposide provide cytotoxic effects against cancer cells, while pegfilgrastim helps manage chemotherapy-induced neutropenia by stimulating the production of neutrophils.

Targets

TOP2A (DNA topoisomerase II)CSF3R (Granulocyte colony-stimulating factor receptor)DNA

Beyond the preview

Go deeper on nimustine + pegfilgrastim + teniposide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on nimustine + pegfilgrastim + teniposide.

Explore the full profile